Literature DB >> 26045785

PCSK9 regulates apoptosis in human neuroglioma u251 cells via mitochondrial signaling pathways.

Ming-Xue Piao1, Ji-Wei Bai1, Peng-Fei Zhang1, Ya-Zhuo Zhang2.   

Abstract

Proprotein convertase subtilisin/kexin type 9 (PCSK9), belongs to a family of proprotein convertases (PCs), encodes a neural apoptosis-regulated convertase 1. However, the precise role of PCSK9 during glioma cells apoptosis has not been reported. Therefore, we examined the effects of knockdown and overexpression of PCSK9 on apoptosis of human neuroglioma U251 cells, and investigated the underlying mechanisms of apoptosis. We found that PCSK9 regulated cells proliferation as determined by CCK-8 and Hoechst staining analysis. In addition, western blot results showed that PCSK9 siRNA promote apoptosis via activation of caspase-3 and down-regulation of the anti-apoptotic proteins, XIAP and p-Akt, while PCSK9 overexpression inhibited apoptosis. Moreover, PCSK9 siRNA improved the ratio of Bax/Bcl-2 which leads to the release of cytochrome c, while PCSK9 overexpression decreased it. Taken together, these data demonstrate that PCSK9 may regulate apoptosis through mitochondrial pathway and is expected to be a promising therapeutic strategy for the malignant glioma.

Entities:  

Keywords:  PCSK9; apoptosis; mitochondrial pathway; neuroglioma

Mesh:

Substances:

Year:  2015        PMID: 26045785      PMCID: PMC4440094     

Source DB:  PubMed          Journal:  Int J Clin Exp Pathol        ISSN: 1936-2625


  27 in total

1.  Glioblastoma multiforme: the terminator.

Authors:  E C Holland
Journal:  Proc Natl Acad Sci U S A       Date:  2000-06-06       Impact factor: 11.205

Review 2.  Genetic alterations associated with adult diffuse astrocytic tumors.

Authors:  Joan Rankin Shapiro
Journal:  Am J Med Genet       Date:  2002-10-30

3.  Implication of the proprotein convertase NARC-1/PCSK9 in the development of the nervous system.

Authors:  Steve Poirier; Annik Prat; Edwige Marcinkiewicz; Joanne Paquin; Babykumari P Chitramuthu; David Baranowski; Benoit Cadieux; Hugh P J Bennett; Nabil G Seidah
Journal:  J Neurochem       Date:  2006-08       Impact factor: 5.372

Review 4.  Molecular biology of PCSK9: its role in LDL metabolism.

Authors:  Jay D Horton; Jonathan C Cohen; Helen H Hobbs
Journal:  Trends Biochem Sci       Date:  2007-01-09       Impact factor: 13.807

Review 5.  Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials.

Authors:  L A Stewart
Journal:  Lancet       Date:  2002-03-23       Impact factor: 79.321

6.  Post-transcriptional regulation of low density lipoprotein receptor protein by proprotein convertase subtilisin/kexin type 9a in mouse liver.

Authors:  Sahng Wook Park; Young-Ah Moon; Jay D Horton
Journal:  J Biol Chem       Date:  2004-09-22       Impact factor: 5.157

7.  NARC-1/PCSK9 and its natural mutants: zymogen cleavage and effects on the low density lipoprotein (LDL) receptor and LDL cholesterol.

Authors:  Suzanne Benjannet; David Rhainds; Rachid Essalmani; Janice Mayne; Louise Wickham; Weijun Jin; Marie-Claude Asselin; Josée Hamelin; Mathilde Varret; Delphine Allard; Mélanie Trillard; Marianne Abifadel; Angie Tebon; Alan D Attie; Daniel J Rader; Catherine Boileau; Louise Brissette; Michel Chrétien; Annik Prat; Nabil G Seidah
Journal:  J Biol Chem       Date:  2004-09-09       Impact factor: 5.157

Review 8.  Primary brain tumours in adults.

Authors:  Anthony Behin; Khe Hoang-Xuan; Antoine F Carpentier; Jean-Yves Delattre
Journal:  Lancet       Date:  2003-01-25       Impact factor: 79.321

Review 9.  Recent advances in the treatment of malignant astrocytoma.

Authors:  David A Reardon; Jeremy N Rich; Henry S Friedman; Darell D Bigner
Journal:  J Clin Oncol       Date:  2006-03-10       Impact factor: 44.544

10.  Retinoids cause apoptosis in pancreatic cancer cells via activation of RAR-gamma and altered expression of Bcl-2/Bax.

Authors:  F Pettersson; A G Dalgleish; R P Bissonnette; K W Colston
Journal:  Br J Cancer       Date:  2002-08-27       Impact factor: 7.640

View more
  15 in total

Review 1.  Biology of proprotein convertase subtilisin kexin 9: beyond low-density lipoprotein cholesterol lowering.

Authors:  Giuseppe Danilo Norata; Hagai Tavori; Angela Pirillo; Sergio Fazio; Alberico L Catapano
Journal:  Cardiovasc Res       Date:  2016-08-05       Impact factor: 10.787

2.  Disruption of endolysosomal trafficking pathways in glioma cells by methuosis-inducing indole-based chalcones.

Authors:  Nneka E Mbah; Jean H Overmeyer; William A Maltese
Journal:  Cell Biol Toxicol       Date:  2016-11-07       Impact factor: 6.691

Review 3.  Antitumor activity and molecular mechanism of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition.

Authors:  Huimin Sun; Wen Meng; Jie Zhu; Lu Wang
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2022-03-21       Impact factor: 3.000

4.  High FITM2 expression promotes cell migration ability of hepatocellular carcinoma by regulating the formation of caveolae and indicates poor patient survival.

Authors:  Yan Chen; Li-Juan Ji; Yan Wang; Xiang-Feng Guo
Journal:  Histol Histopathol       Date:  2021-10-21       Impact factor: 2.303

5.  Oxidized low-density lipoprotein (oxLDL) affects load-free cell shortening of cardiomyocytes in a proprotein convertase subtilisin/kexin 9 (PCSK9)-dependent way.

Authors:  Klaus-Dieter Schlüter; Annemarie Wolf; Martin Weber; Rolf Schreckenberg; Rainer Schulz
Journal:  Basic Res Cardiol       Date:  2017-09-14       Impact factor: 17.165

Review 6.  PCSK9 signaling pathways and their potential importance in clinical practice.

Authors:  Michał Wiciński; Jarosław Żak; Bartosz Malinowski; Gabriela Popek; Grzegorz Grześk
Journal:  EPMA J       Date:  2017-08-14       Impact factor: 6.543

7.  Inhibition of PCSK9 protects against radiation-induced damage of prostate cancer cells.

Authors:  Si-Shun Gan; Jian-Qing Ye; Lei Wang; Fa-Jun Qu; Chuan-Min Chu; Yi-Jun Tian; Wei Yang; Xin-Gang Cui
Journal:  Onco Targets Ther       Date:  2017-04-12       Impact factor: 4.147

Review 8.  Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) in the Brain and Relevance for Neuropsychiatric Disorders.

Authors:  Emma M O'Connell; Falk W Lohoff
Journal:  Front Neurosci       Date:  2020-06-12       Impact factor: 4.677

9.  Pretreatment With PCSK9 Inhibitor Protects the Brain Against Cardiac Ischemia/Reperfusion Injury Through a Reduction of Neuronal Inflammation and Amyloid Beta Aggregation.

Authors:  Nattayaporn Apaijai; Dalila Monica Moisescu; Siripong Palee; Christian Mervyn McSweeney; Napatsorn Saiyasit; Chayodom Maneechote; Chiraphat Boonnag; Nipon Chattipakorn; Siriporn C Chattipakorn
Journal:  J Am Heart Assoc       Date:  2019-01-22       Impact factor: 5.501

10.  Hepatocellular carcinoma-associated hypercholesterolemia: involvement of proprotein-convertase-subtilisin-kexin type-9 (PCSK9).

Authors:  Dipti Athavale; Surbhi Chouhan; Vimal Pandey; Shyamananda Singh Mayengbam; Snahlata Singh; Manoj Kumar Bhat
Journal:  Cancer Metab       Date:  2018-10-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.